From owner-chemistry@ccl.net Mon Oct 28 18:15:01 2013 From: "Diana O Rourke diana.orourke|a|certara.com" To: CCL Subject: CCL: Webinar on drug safety assessment, automatic extraction of structure-activity relationships Message-Id: <-49284-131028164536-25650-O7XG1NDYSKCLmqnD4fNlVQ{=}server.ccl.net> X-Original-From: "Diana O'Rourke" Content-Language: en-US Content-Type: multipart/alternative; boundary="_000_BDEBE0F798A180419DDCD69746D7F8F30BEA55B1E5s01itwsex01_" Date: Mon, 28 Oct 2013 15:45:25 -0500 MIME-Version: 1.0 Sent to CCL by: "Diana O'Rourke" [diana.orourke#certara.com] --_000_BDEBE0F798A180419DDCD69746D7F8F30BEA55B1E5s01itwsex01_ Content-Type: text/plain; charset=WINDOWS-1252 Content-Transfer-Encoding: quoted-printable The next webinar in Certara's Drug Discovery Webinar Series is this Wednesd= ay, October 30, at 11am New York (8am San Diego, 4pm London, 5pm Paris): D= rug safety assessment through automatic extraction of structure-activity re= lationships The webinar will present an improved workflow for automatic building of 3D = QSAR models from chemical biology databases such as ChEMBL. The resulting "= library of 3D-QSAR models" can be used to identify and make predictions for= both on- or off-target effects of drug candidate molecules. Examples will = be given to showcase simple and straightforward visual analysis of structur= e-activity relationships that yield insights that would not be revealed on = the basis of chemical similarity. For more information and/or to register, go to www.certara.com/qsea-webinar= Also, you might be interested to know that future upcoming webinars, and li= nks to the replay of past webinars in the series, can be found on here: ww= w.certara.com/drug-discovery-webinar-series Best regards, Diana O'Rourke Marketing Director Certara diana.orourke(at)certara.com www.certara.com=0A=0A=0ANOTICE: The information co= ntained in this electronic mail message is intended only for the personal a= nd confidential=20=0Ause of the designated recipient(s) named above. This m= essage may be an attorney-client communication, may be protected=20=0Aby th= e work product doctrine, and may be subject to a protective order. As such,= this message is privileged and=20=0Aconfidential. If the reader of this me= ssage is not the intended recipient or an agent responsible for delivering = it to=20=0Athe intended recipient, you are hereby notified that you have re= ceived this message in error and that any review,=20=0Adissemination, distr= ibution, or copying of this message is strictly prohibited. If you have rec= eived this=20=0Acommunication in error, please notify us immediately by tel= ephone and e-mail and destroy any and all copies of this=20=0Amessage in yo= ur possession (whether hard copies or electronically stored copies). Thank = you.=0A=0AbuSp9xeMeKEbrUze --_000_BDEBE0F798A180419DDCD69746D7F8F30BEA55B1E5s01itwsex01_ Content-Type: text/html; charset=WINDOWS-1252 Content-Transfer-Encoding: quoted-printable =0A =
=0A
=0A

The next webinar in = Certara’s Drug Discovery Webinar Series is this Wednesday, October 30= , at 11am New York (8am San Diego, 4pm London, 5pm Paris):  Drug safet= y assessment through automatic extraction of structure-activity relationshi= ps

The webinar will present an improved workflow for automatic building of= 3D QSAR models from chemical biology databases such as ChEMBL. The resulti= ng “library of 3D-QSAR models” can be used to identify and make= predictions for both on- or off-target effects of drug candidate molecules= . Examples will be given to showcase simple and straightforward visual anal= ysis of structure-activity relationships that yield insights that would not= be revealed on the basis of chemical similarity.

 <= /p>

For more informati= on and/or to register, go to www.certara.com/qsea-webinar

 

Also, you might be interested to= know that future upcoming webinars, and links to the replay of past webina= rs in the series, can be found on here:  www.certara.com/drug-discovery-w= ebinar-series

 

<= p class=3DMsoNormal>Best regards,

Diana = O’Rourke

Marketing Director

Certara

dia= na.orourke(at)certara.com

www.certara.com<= /b>

 

=0A =
=0A
=0A=0A=0A=0A=0A
NOTICE: The in= formation contained in this electronic mail message is intended only for th= e personal and confidential use of the designated recipient(s) named above.= This message may be an attorney-client communication, may be protected by = the work product=20=0Adoctrine, and may be subject to a protective order. A= s such, this message is privileged and confidential. If the reader of this = message is not the intended recipient or an agent responsible for deliverin= g it to the intended recipient, you are hereby notified that you have=20=0A= received this message in error and that any review, dissemination, distribu= tion, or copying of this message is strictly prohibited. If you have receiv= ed this communication in error, please notify us immediately by telephone a= nd e-mail and destroy any and all copies of=20=0Athis message in your posse= ssion (whether hard copies or electronically stored copies). Thank you.=0A
=0A
=0AbuSp9xeMeKEbrUze=0A
=0A --_000_BDEBE0F798A180419DDCD69746D7F8F30BEA55B1E5s01itwsex01_--